…
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source; and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists; Nanox.CONNECT to receive local regulatory approvals and explore and evaluate the business model and the potential service; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data of existing computed tomography scans; and Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers and mobile imaging service providers, urgent care facilities, and multi-specialty physician groups. In addition, the company provides Real+ Osteoporosis Care Management Platform, a osteoporosis care management software platform; AI-Based Aortic Valve Calcification Measurement, an artificial intelligence"based solution; AI-Based Body Composition Measurement, an artificial intelligence"based body composition analysis capability; and Nanox Health IT, a healthcare information technology services provider that serves hospitals and other healthcare organizations. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Petah Tikva, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Nano-X Imaging Ltd develops a compact digital X‑ray system using electronic beam technology to lower cost and enable mobile radiography, aiming to expand access in emerging and underserved markets. Long-term growth drivers include replacement of legacy analog systems and expansion into software and services, which could support scalable recurring revenue and broader adoption.
Key risks are regulatory and reimbursement uncertainty, commercialization and scaling execution, competition from established imaging vendors, and potential need for additional capital.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -76.81M | -53.87M | -61.12M | -108.92M | -61.85M |
| Net income | -75.02M | -53.52M | -60.78M | -105.24M | -61.80M |
| Selling general administrative | 24.46M | 24.10M | 26.01M | 41.25M | 34.71M |
| Selling and marketing expenses | 2.63M | 1.65M | 2.38M | 4.38M | 7.03M |
| Gross profit | -12.79M | -10.61M | -6.59M | -6.88M | -1.51M |
| Reconciled depreciation | 11.70M | 11.73M | 11.64M | 11.51M | 2.29M |
| Ebit | -60.70M | -56.75M | -59.50M | -109.71M | -63.85M |
| Ebitda | -49.00M | -45.01M | -47.69M | -37.19M | -61.56M |
| Depreciation and amortization | 11.70M | 11.73M | 11.81M | 72.52M | 2.29M |
| Operating income | -60.70M | -56.75M | -62.59M | -109.71M | -61.56M |
| Other operating expenses | 73.72M | 68.03M | 72.49M | 87.79M | 62.86M |
| Interest expense | - | - | - | 60.22M | 2.00M |
| Tax provision | -1.79M | -0.36M | -1.29M | -3.68M | -0.05M |
| Interest income | 1.42M | 2.87M | 1.65M | - | - |
| Net interest income | 1.42M | 2.87M | 1.18M | 0.79M | -0.29M |
| Income tax expense | -1.79M | -0.36M | -0.34M | -3.68M | -0.05M |
| Total revenue | 13.02M | 11.28M | 9.90M | 8.58M | 1.30M |
| Total operating expenses | 47.91M | 46.14M | 56.00M | 72.33M | 60.05M |
| Cost of revenue | 25.81M | 21.89M | 16.50M | 15.46M | 2.82M |
| Total other income expense net | -16.11M | 2.87M | 1.47M | 0.79M | -0.29M |
| Net income from continuing ops | -75.02M | -53.52M | -103.36M | -105.24M | -61.80M |
| Net income applicable to common shares | - | - | - | -113.24M | -61.80M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 162.16M | 210.00M | 218.65M | 253.93M | 363.17M |
| Intangible assets | 59.87M | 70.00M | 80.61M | 91.22M | 160.12M |
| Other current assets | 2.10M | 2.18M | 2.32M | 1.45M | 1.97M |
| Total liab | 22.43M | 20.88M | 23.13M | 29.25M | 71.02M |
| Total stockholder equity | 139.73M | 189.12M | 195.51M | 224.68M | 292.15M |
| Other current liab | 9.38M | 7.82M | 7.33M | 12.53M | 48.34M |
| Common stock | 0.20M | 0.18M | 0.17M | 0.16M | 0.15M |
| Capital stock | 0.20M | 0.18M | 0.17M | 0.16M | 0.15M |
| Retained earnings | -448.77M | -373.75M | -320.23M | -251.46M | -146.21M |
| Other liab | - | - | - | 8.30M | 13.53M |
| Good will | 0.32M | 0.00M | 0.00M | 7.42M | 58.30M |
| Other assets | - | - | 0.00M | 34.67M | 1.18M |
| Cash | 49.15M | 39.30M | 56.42M | 38.46M | 66.64M |
| Total current liabilities | 16.89M | 13.97M | 15.52M | 17.07M | 52.75M |
| Current deferred revenue | 0.53M | 0.14M | 0.54M | 0.18M | 0.25M |
| Net debt | -41.30M | -31.86M | -48.03M | -33.84M | -60.87M |
| Short term debt | 4.09M | 3.81M | 4.35M | 0.74M | 1.03M |
| Short long term debt | 3.14M | 3.06M | 3.49M | - | 0.14M |
| Short long term debt total | 7.85M | 7.45M | 8.40M | 4.62M | 5.77M |
| Other stockholder equity | 588.30M | 562.69M | 515.89M | 477.95M | 438.82M |
| Property plant equipment | - | - | - | 12.96M | 39.16M |
| Total current assets | 66.79M | 78.68M | 88.64M | 82.46M | 94.86M |
| Long term investments | - | - | 0.00M | 25.20M | 67.84M |
| Net tangible assets | - | - | - | 118.04M | 132.02M |
| Short term investments | 10.46M | 33.90M | 26.01M | 39.16M | 22.07M |
| Net receivables | 2.01M | 1.80M | 1.48M | 0.98M | 1.05M |
| Long term debt | - | - | - | 3.48M | 3.80M |
| Inventory | 3.07M | 1.49M | 2.36M | 2.41M | 3.13M |
| Accounts payable | 2.89M | 2.21M | 3.30M | 3.62M | 3.13M |
| Accumulated other comprehensive income | 0.00M | -0.00M | -0.30M | -1.97M | -0.61M |
| Non currrent assets other | 1.63M | 11.79M | 2.16M | 2.93M | 1.18M |
| Non current assets total | 95.37M | 131.32M | 130.01M | 171.47M | 268.31M |
| Capital lease obligations | 4.71M | 4.38M | 4.91M | 1.14M | 1.83M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 33.80M | -20.05M | 45.92M | 14.61M | -116.32M |
| Change to liabilities | - | - | - | 0.39M | 0.00M |
| Total cashflows from investing activities | 29.37M | -20.05M | 35.43M | 14.61M | -116.32M |
| Net borrowings | - | - | 0.00M | -0.14M | -0.14M |
| Total cash from financing activities | 21.37M | 39.50M | 27.25M | 0.80M | 7.38M |
| Change to operating activities | - | - | - | 10.97M | 10.97M |
| Net income | -75.02M | -53.52M | -60.78M | -105.24M | -61.80M |
| Change in cash | 9.85M | -17.07M | 17.85M | -28.24M | -147.01M |
| Begin period cash flow | 39.30M | 56.38M | 38.53M | 66.77M | 213.78M |
| End period cash flow | 49.15M | 39.30M | 56.38M | 38.53M | 66.77M |
| Total cash from operating activities | -40.79M | -36.60M | -44.78M | -43.38M | -38.07M |
| Issuance of capital stock | 21.20M | 37.83M | 27.14M | 0.00M | 0.00M |
| Depreciation | 11.70M | 11.73M | 11.81M | 11.51M | 2.29M |
| Other cashflows from investing activities | -0.20M | 0.05M | -0.37M | - | -116.32M |
| Change to inventory | -0.33M | -0.28M | 0.00M | - | 0.86M |
| Change to account receivables | 0.11M | -0.32M | -0.51M | 0.07M | -0.04M |
| Other cashflows from financing activities | - | 1.67M | 0.11M | 0.80M | 7.38M |
| Change to netincome | - | - | - | 46.91M | 23.73M |
| Capital expenditures | 4.21M | 2.77M | 3.30M | 7.17M | 23.16M |
| Change in working capital | 2.77M | -1.13M | -7.48M | -16.95M | 2.75M |
| Stock based compensation | 4.19M | 7.26M | 6.84M | 18.62M | 18.81M |
| Other non cash items | 17.54M | -0.57M | 5.21M | 52.40M | -0.00M |
| Free cash flow | -45.00M | -39.37M | -48.08M | -50.56M | -61.23M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NNOX Nano X Imaging Ltd |
-0.01 3.26% |
0.24 | - | - | 3.45 | 0.76 | 2.03 | -7.41 |
| ABT Abbott Laboratories |
-0.03 0.03% |
109.93 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-3.04 2.90% |
101.80 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-9.21 2.75% |
325.87 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-2.15 4.12% |
49.85 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source; and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists; Nanox.CONNECT to receive local regulatory approvals and explore and evaluate the business model and the potential service; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data of existing computed tomography scans; and Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers and mobile imaging service providers, urgent care facilities, and multi-specialty physician groups. In addition, the company provides Real+ Osteoporosis Care Management Platform, a osteoporosis care management software platform; AI-Based Aortic Valve Calcification Measurement, an artificial intelligence"based solution; AI-Based Body Composition Measurement, an artificial intelligence"based body composition analysis capability; and Nanox Health IT, a healthcare information technology services provider that serves hospitals and other healthcare organizations. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Petah Tikva, Israel.
| Name | Title | Year Born |
|---|---|---|
| Ms. Marina Gofman Feler | Chief Legal Officer | NA |
| Mr. Ran Poliakine | Founder & Chairman | 1969 |
| Mr. Erez I. Meltzer | CEO & Director | 1957 |
| Ran Daniel | Chief Financial Officer | 1968 |
| Mr. Tal Shank | VP of Corp. Devel. | 1978 |
| Ms. Tamar Aharon Cohen | Exec. VP & Chief Marketing Officer | 1977 |
| Mr. Gilad Yron | Chief Bus. Officer | 1973 |
| Mr. James M. Dara | GM of Source & Services Division and Head of Nanox USA | 1970 |
| Ms. Lydia Edwards | Pres of Nanox US | NA |
| Dr. Ilung Kim Ph.D. | Head of Nanox Korea | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.